Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Atea Pharmaceuticals, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
AVIR
Nasdaq
2834
ateapharma.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Atea Pharmaceuticals, Inc.
Is Medpace (MEDP) Stock Outpacing Its Medical Peers This Year?
- Nov 13th, 2026 6:40 am
Atea Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary
- Nov 9th, 2026 7:10 pm
Atea Pharma (AVIR) Q3 2026 Earnings Call Transcript
- Nov 9th, 2026 6:00 pm
What Atea Pharmaceuticals (AVIR) Said on Its Q3 Earnings Call
- Nov 9th, 2026 5:14 pm
Atea Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
- Nov 9th, 2026 2:05 pm
Atea Pharmaceuticals Secures Credit Facility for Up to $200 Million from Hercules Capital
- Nov 9th, 2026 5:00 am
Atea Pharmaceuticals to Host Third Quarter 2026 Financial Results and Business Update Conference Call on November 9, 2026
- Nov 2nd, 2026 2:05 pm
Atea Pharmaceuticals to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
- Sep 8th, 2026 5:00 am
Atea (AVIR) Q2 2026 Earnings Call Transcript
- Aug 19th, 2026 3:13 pm
Atea Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary
- Aug 12th, 2026 6:55 pm
Atea Pharmaceuticals Q2 Earnings Call Highlights
- Aug 12th, 2026 4:04 pm
Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
- Aug 12th, 2026 2:05 pm
Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026
- Aug 5th, 2026 5:00 am
FDA reviewers criticize Replimune drug; ProMIS climbs on Alzheimer’s data
- Jul 29th, 2026 5:00 am
Atea Pharmaceuticals Says Hepatitis C Drug Matches Gilead's in Pivotal Trial
- Jul 29th, 2026 3:45 am
Atea Pharmaceuticals Says Combination Drug Meets Endpoints in Phase 3 Hepatitis C Trial
- Jul 28th, 2026 6:27 am
Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus
- Jul 28th, 2026 5:00 am
Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus
- Jul 14th, 2026 5:00 am
Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
- Jun 25th, 2026 5:00 am
Atea Pharmaceuticals (AVIR) Upgraded to Buy: Here's What You Should Know
- Jun 18th, 2026 10:00 am
Scroll